It’s not every day you see a company show the CEO the door and announce a strategic review all at once, but that’s exactly what Kenvue did. In a bold move that turned heads on Wall Street, the consumer health spin-off from Johnson & Johnson that owns storied brands like Tylenol and Band-Aid, signaled it’s ready to rethink everything from who’s steering the ship to where it’s headed.
Behind the scenes, activist investors have been turning up the heat, pushing for governance changes and demanding sharper execution. Now, with the top job vacant and “strategic alternatives” on the table, Kenvue’s direction has never been more uncertain or more consequential.